16:37 uur 22-09-2016

Kankerdiagnosebedrijf iCareDx verandert naam in Acuamark

NEW YORK–(BUSINESS WIRE)– iCareDx, Inc., een biotechnologisch bedrijf met focus op bloedtests voor vroege signalering van kanker, heeft vandaag bekendgemaakt dat het zijn naam verandert in Acuamark Diagnostics, Inc. In samenhang met de naamsverandering is de website van het bedrijf te tegenwoordig te vinden onder de naam www.acuamarkdx.com.

Wereldwijd sterven dagelijks 22.000 mensen aan kanker. Over het algemeen is de kans op overleven groter als kanker vroeg wordt gesignaleerd. Een accurate, gebruiksvriendelijke en betaalbare technologie voor vroege opsporing van kanker kan het aantal overlijdensgevallen door kanker en kankergerelateerde zorgkosten flink verlagen.



Early-Cancer Detection Company iCareDx Announces Corporate Name Change To Acuamark Diagnostics


NEW YORK–(BUSINESS WIRE)– iCareDx, Inc., a biotechnology company focused on blood-based early detection of cancer, today announced that it has changed its name to Acuamark Diagnostics, Inc. In conjunction with its corporate name change, the Company’s website will be available at www.acuamarkdx.com.

Globally, over 22,000 people die of cancer each day. When cancer is detected at the early stages, survival rates are generally still high. Finding cancer early with an accurate, convenient and affordable technology, and attacking it early, can vastly reduce cancer deaths, and substantially lower cancer-related healthcare expenditures.

Dr. Bernard Peperstraete, CEO of Acuamark Diagnostics, Inc. (formerly iCareDx, Inc.) stated, “Our team is excited to re-brand the Company as Acuamark Diagnostics. The name “Acuamark” incorporates several elements that play to the essence of our corporate mission, and well embodies the progress we have made towards developing an accurate diagnostic screening technology to detect low-abundance tumor markers from liquids at the earliest stages of cancer.”

Dr. Francis Barany, PhD, Professor of Microbiology and Immunology at the Weill Cornell Medicine, and lead inventor of Acuamark Diagnostics’ molecular detection technologies, adds: “In addition, the name Acuamark Diagnostics is a reflection that each cancer leaves a unique watermark in our bodies, and as with a watermark, it is barely visible, requiring one to see it in a different light.”

About Acuamark Diagnostics Inc.

Acuamark Diagnostics is a biotechnology company focused on developing screening tests technologies for blood-based early detection of cancer. Acuamark Diagnostics’ technology allows for highly accurate screening of blood to detect cancer markers at the early cancer stages, before the cancer becomes untreatable. Backed by a highly experienced team, it is Acuamark Diagnostics’ mission to contribute to the global battle against cancer by detecting and attacking cancer through high-precision, early detection.

For more information, please visit www.acuamarkdx.com, or contact us at info@acuamarkdx.com.


Acuamark Diagnostics, Inc.
Bernard Peperstraete, MD
Chief Executive Officer

Check out our twitter: @NewsNovumpr